The startup develops pharmaceutical drugs that include a Rho Kinase inhibitor for treating normal-tension glaucoma and a neutrophil elastase inhibitor for managing nonalcoholic fatty liver disease. These targeted therapies enable healthcare providers to effectively treat patients with these chronic conditions without the complications associated with traditional treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Normal-tension glaucoma and nonalcoholic fatty liver disease are chronic conditions that require effective management to prevent disease progression and complications. Current treatments may have limitations or associated side effects, highlighting the need for targeted therapies.
Solution
This startup is developing pharmaceutical drugs to address normal-tension glaucoma and nonalcoholic fatty liver disease. Their lead candidate for glaucoma is a Rho Kinase (ROCK) inhibitor designed to lower intraocular pressure and improve blood flow to the optic nerve. The company's drug for nonalcoholic fatty liver disease is a neutrophil elastase inhibitor intended to reduce inflammation and fibrosis in the liver. These targeted therapies aim to provide healthcare providers with more effective and well-tolerated options for managing these chronic conditions.
Target Audience
The primary target audience includes healthcare providers, such as ophthalmologists and hepatologists, who treat patients with normal-tension glaucoma and nonalcoholic fatty liver disease.
Features
- Rho Kinase (ROCK) inhibitor for normal-tension glaucoma
- Neutrophil elastase inhibitor for nonalcoholic fatty liver disease
- Targeted therapies designed to minimize off-target effects